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Abstract
Objective: An insertion/deletion (I/D) variant in the angiotensin-converting enzyme (ACE) gene was associated with ACE
inhibitor (ACEI)–related cough in previous studies. However, the results were inconsistent. Our objective was to assess the
relationship between the ACE I/D polymorphism and ACEI-related cough by meta-analysis and to summarize all studies that
are related to ACE I/D polymorphism and ACEI-cough and make a summary conclusion to provide reference for the
researchers who attempt to conduct such a study.
Methods: Databases including PubMed, EMbase, Cochrane Library, and China National Knowledge Infrastructure, were
searched for genetic association studies. Data were extracted by two independent authors and pooled odds ratio (OR) with
95% confidence interval (CI) was calculated. Metaregression and subgroup analyses were performed to identify the source
of heterogeneity.
Results: Eleven trials, including 906 cases (ACEI-related cough) and 1,175 controls, were reviewed in the present meta-
analysis. The random effects pooled OR was 1.16 (95%CI: 0.78–1.74, p=0.46) in the dominant model and 1.61 (95%CI: 1.18–
2.20, p=0.003) in the recessive model. Heterogeneity was found among and within studies. Metaregression indicated that
the effect size was positively associated with age and negatively associated with follow-up duration of ACEI treatment.
Subgroup analysis revealed a significant association between ACE I/D polymorphism and ACEI-related cough in studies with
mean age .60 y, but not in studies with mean age #60 y. No heterogeneity was found within each mean age subgroup.
We also found no association between ACE I/D polymorphism and ACEI-related cough in studies with follow-up.2m oo ri n
studies in Caucasians. No heterogeneity was detected in these two subgroups.
Conclusions: Synthesis of the available evidence supports ACE I/D polymorphism as an age-dependent predictor for risk of
ACEI-related cough.
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Introduction
Angiotensin-converting enzyme inhibitors (ACEI) have been
used for 30 years to treat cardiovascular diseases. In addition to
their antihypertensive effects, ACEI are now widely used for
congestive heart failure, acute myocardial infarction, and diabetic
nephropathy [1–5]. However, a persistent dry cough associated
with ACEI therapy is the most common adverse effect and the
most frequent reason for discontinuation of the drug [6,7]. The
prevalence of cough varies from 0.7% to 53% worldwide and has
been reported to be higher in Asian populations than in Caucasian
populations [8–12].
The pathogenesis of ACEI-related cough remains unclear. It
has been speculated that a local accumulation of bradykinin may
play a major role in ACEI-related cough. This accumulation may
lead to the activation of proinflammatory peptides (e.g., substance
P, prostaglandins, neuropeptide Y, and phospholipase C and/or
A2) and local release of histamine in the airways [6,7]. ACE plays
an essential role as a kininase in the degradation of bradykinin,
and has a higher affinity for bradykinin than for angiotensin I
[13,14].
An insertion/deletion (ID) polymorphism of the human ACE
gene on chromosome 17q23 comprising the presence or absence
of a 287 base pair (bp) insert in intron 16 was described by Rigat
et al. in 1990 [15]. Subsequently, some studies confirmed that the
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gene effect at the ACE gene locus, which controls up to 16–24% of
the variability in ACE levels [16,17]. Patients with genotype II
have the lowest serum ACE levels compared to those with ID or
DD [16]. Therefore, genotype II would be expected to be
associated with an increased risk of ACEI-related cough. Although
the results of several studies supported this hypothesis [18,19], but
the relationship was not replicated in other studies [20–22]. In the
present study, we used a meta-analysis to address these
discrepancies and to investigate the association between the ID
polymorphism and ACEI-related cough.
Methods
Database Searches
Using the term ‘‘ACE’’ or ‘‘ACEI’’ paired with ‘‘cough’’ and
‘‘polymorphism’’ without language restriction, we systematically
searched PubMed (http://www.ncbi.nlm.nih.gov/pubmed; 1950–
March 2011), EMbase (http://www.embase.com; 1950–March
2011), China National Knowledge Infrastructure (CNKI) (http://
www.cnki.net; 1979–March 2011), the Cochrane Library (http://
www.cochrane.org), and reviews and reference lists of relevant
articles. The last search was performed in March 2011.
Study Selection
We selected studies as follows: (1) unrelated case-control studies
and cohort studies; (2) complete data with genotype and allele
frequencies; (3) genotype frequency of cases and controls is within
Hardy–Weinberg equilibrium; and (4) studies in which the ID
polymorphism has been determined. All of the literature searches
were independently reviewed by two of the authors (Ya-Feng Li
and Yun-Fei Bian).
Data Extraction
We extracted the following information from each study: first
author, journal, year of publication, study population, demo-
graphics, number of cases and controls for ID genotype, type and
dosage of ACEI, and follow-up time. The frequencies of the alleles
and the genotypic distributions were extracted or calculated for
both the cases and the controls.
Statistical Analysis
Data from the meta-analysis were analyzed using Stata software
(Version 9.0; Stata Corportation, College Station, TX, USA) and
REVMAN software (Version 5.0; Cochrane Collaboration,
Oxford, UK). The significance of the association for the dominant
model (II/ID versus DD genotypes), the recessive model (II versus
ID/DD genotypes), and the allele contrast I versus D were
evaluated for 11 studies separately. All associations were indicated
as odds ratios (ORs) with 95% confidence interval (CI). The
pooled ORs were estimated using random effects (RE) and fixed
effects (FE) models based on the individual Ors [23].
Statistical heterogeneity between studies was formally tested
with Cochran’s test. We also determined the I
2 statistic, which
yields values between 0% and 100%, with higher values denoting
greater degree of heterogeneity (0%#I
2,25%: no heterogeneity;
25%#I
2,50%: moderate heterogeneity; 50%#I
2,75%: large
heterogeneity; and 75%#I
2,100%: extreme heterogeneity) [24].
Metaregression was used to explore the source of potential
heterogeneity. Subgroup analyses were performed to further
identify the possible source of heterogeneity by comparing results
obtained from subsets of studies grouped by mean age of cases,
proportion of males, and study population.
Publication bias was assessed with the Egger regression test and
represented graphically by use of Begg’s funnel plots of logOR
compared with the standard error (SE) of logOR [25].
A chi-square (x
2) test was applied to determine if genotype
distributions of the control population reported conformed to
Hardy-Weinberg equilibrium (HWE; P,0.05 was considered
significant), and the study that the genotype distributions in the
controls were significantly deviated from HWE was excluded from
our sensitive analysis [26]. All p values were two-tailed and p,0.05
was considered statistically significant.
Results
Search Results
A total of 18 case-control studies and cohort studies were
identified in a systematic search of PubMed, EMbase, CNKI,
Cochrane Library, and references cited in reviews and research
articles. Six studies were excluded because they were not within
Hardy–Weinberg equilibrium (Table 1) [27–32]. One study was
excluded because the frequencies of the genotypic distributions
cannot be extracted from the paper [33]. Eleven studies were
finally included in this meta-analysis [18–22,34–39]. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) checklist and flow diagram were respectively stated in
Table S1 and Figure S1.
Study Characteristics
In total, the study contained 906 hypertensives with ACEI-
related cough as cases and 1,175 hypertensives without ACEI-
related cough as controls. Table 2 shows the details of these
studies. The sample size of the 11 studies ranged from 18 to 351
cases. The average age of ACEI-related cough subjects in the 11
studies ranged from 53 to 72.1 y (median age: 60 y). The
percentage of males in the studies ranged from 18.3%–71.2%
(median: 62%). The ACEIs used in the studies varied. The
duration of follow-up of ACEI treatment varied from 0.5 to 36 mo
(median: 2 mo). Five studies matched the case and control groups
with regard to age and sex [34–37,39]. Three studies were not age-
or sex-matched [18,19,22], and we could not obtain this
information for the remaining three studies [20,21,38]. The
populations of seven studies were Asian [18,19,35–39], and the
remaining four study populations were Caucasian [20–22,34].
Association between Genotypes and ACEI-related Cough
Table 1 shows the genotype distribution and allele frequencies
in the original 18 studies. In the 11 studies that were within
Hardy–Weinberg equilibrium [18–22,34–39], the distributions of
genotypes II and DD were significantly different between Asian
and Caucasian study populations (II: 36.4% versus 24.9%,
p=0.0001 and DD: 16.3% versus 28.6%, p,0.0001, respectively,
in Asians and Caucasians). No difference was found in the
distribution of genotype ID between Asians and Caucasians
(47.3% versus 46.5%, respectively; p=0.8430).
The RE and FE pooled ORs for the recessive model were 1.61
(95%CI: 1.18 to 2.20, p=0.003) and 1.37 (95%CI: 1.14 to 1.66,
p=0.001), respectively (Figure 1A, 1B). However, we found
heterogeneity of the pooled ORs (I
2=49.8%, p=0.030). To
determine the sources of heterogeneity, metaregression and
subgroup analyses were performed. Metaregression analysis of
data showed that the mean age of hypertensives with ACEI-related
cough and the follow-up duration of ACEI treatment contributed
to the heterogeneity. The mean age was positively associated with
the OR (regression coefficient=0.11, 95%CI: 0.05 to 0.17,
p=0.001), and the duration of treatment was negatively associated
ACE Gene Polymorphism and Cough
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20.01, p=0.008). The type of ACEI, the proportion of males, and
the study population were not effect modifiers.
To further investigate the heterogeneity, we performed sub-
group analyses (Table 3). Other than mean age, duration of
treatment, and study populations, we did not find any evidence of
heterogeneity of effects in the subgroup analyses, including the
category of ACEI or the sex ratio. We calculated the median value
of the mean ages of hypertensives with ACEI-related cough and
defined the mean age #60 y (lower median) for all studies to be
one subgroup; the mean age .60 y (upper median) was assigned
to the other subgroup. No heterogeneity existed in either the
younger median subgroup (#60 y) or the older median subgroup
(.60 y) (I
2=1%, p=0.403 and I
2=0%, p=0.773; respectively).
The FE pooled ORs (1.12 [95%CI: 0.88 to 1.42, p=0.360] versus
2.39 [95%CI: 1.67 to 3.42, p,0.001]) were significantly different
Table 1. The Distribution of the I/D Genotype for Cases and Controls.
References Year Cases Controls
Distribution of I/D
genotype
Allele
Frequency HWE P
Distribution of I/D
genotype
Allele
Frequency HWE P
II ID DD I D II ID DD I D
W. W. Yeo, et al. 1992 5 6 7 16 20 .0.05 2671 0 2 0 .0.05
K. Furuya, et al. 1994 19 12 0 50 12 .0.05 25 35 11 85 57 .0.05
C. Kreft-Jais, et al. 1994 15 29 27 59 83 .0.05 12 33 30 57 93 .0.05
I.G. Chadwick, et al. 1994 6 12 13 24 38 .0.05 58 97 66 213 229 .0.05
R.Y. Zee, et al. 1998 23 41 35 87 111 .0.05 12 37 21 61 79 .0.05
Je Hyeong Kim, et al. 1999 6 7 24 19 55 ,0.05 57 55 290 169 635 ,0.05
Wu Jianqing, et al. 1999 24 15 13 63 41 ,0.05 21 19 30 61 79 ,0.05
H. Okumura, et al. 2000 20 16 6 56 28 .0.05 19 31 4 69 39 .0.05
Y-J Lee, et al. 2001 46 44 3 136 50 .0.05 33 48 15 114 78 .0.05
S Mukae, et al. 2002 8 45 17 61 79 ,0.05 28 73 19 129 111 ,0.05
Wang huijuan, et al. 2003 18 14 8 50 30 .0.05 35 36 34 106 104 ,0.05
S-M Yang, et al. 2003 21 20 11 62 42 .0.05 10 21 19 41 59 .0.05
J Lu, et al. 2003 148 163 40 459 243 .0.05 160 165 40 485 245 .0.05
Ye Ruan-jia, et al. 2004 27 14 7 68 28 ,0.05 16 35 28 67 91 .0.05
Shi Meijun, et al. 2008 28 15 8 71 31 ,0.05 17 36 28 70 92 .0.05
Tang Xiao-Hong, et al. 2008 32 26 10 90 46 .0.05 24 48 26 96 100 .0.05
S. W. Woo, et al. 2009 26 16 8 68 32 .0.05 24 31 5 79 41 .0.05
References in bold-face were studies within Hardy–Weinberg equilibrium.
doi:10.1371/journal.pone.0037396.t001
Table 2. Characteristics of Eligible Studies Considered in the Meta-Analysis.
Reference Population ACEIs
Dose
(mg/d)
Interval
(months) Case Control
Age- and sex-
Matched
Mean
age (y) Number Male %(n)
Mean age
(y) Number Male %(n)
20 Caucasian enalapril (81.3%) 20 6 53 71 – 47 75 – Unknown
34 Asian benazepril – 36 55.4 351 52.7 (185) – 365 56.2(205) Yes
21 Caucasian lisinopril 20 1.5 57 99 47.5(47) 58.4 70 34.3(24) No
31 Caucasian enalapril 10–20 6 – 18 – – 15 – Yes
36 Asian – – 3 58.5 50 62.0(31) 58.3 60 61.7(37) Yes
32 Asian trandolapril 1 1 60 42 64.3(27) 59 54 53.7(29) Yes
35 Asian captopril 50 2 61.8 68 – – 98 – Unknown
18 Asian perindopril 4 0.5 63.3 93 18.3(17) 58.6 96 68.8(66) No
17 Asian enalapril (75.5%) 20 – 65 31 51.6(16) 58 71 50.7(36) No
33 Asian lisinopril – 1 72.1 52 71.2(37) 72.6 50 78.0(39) Yes
19 Caucasian enalapril – – – 31 – – 221 – Unknown
–, not reported.
doi:10.1371/journal.pone.0037396.t002
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subgroups were categorized by the median of follow-up duration
of ACEI treatment, heterogeneity was also reduced in both the
shorter duration median subgroup (#2 mo) and the longer
duration median subgroup (.2 mo) (I
2=0%, p=0.705 and
I
2=7%, p=0.359; respectively). The FE pooled ORs of the two
ACEI treatment duration median subgroups different significantly
(2.02 [95%CI: 1.47 to 2.79, p,0.001] versus 1.06 [95% CI: 0.82,
1.37, p=0.660]) (p=0.0016).
We also found reduced heterogeneity (I
2=0%; p=0.485) and
an FE pooled OR of 1.22 (95%CI: 0.77 to 1.93, p=0.390) for the
Caucasian studies. However, the seven Asian population studies
Figure 1. Random effect (A) and fixed effect (B) pooled ORs for the recessive model. Subgroup analyses in recessive model were also
carried out (B). Studies were first divided by ethnicity, then Asian population studies were divided into two subgroups: #60 y old (lower median) and
.60 y old (upper median). The fixed-effect model was used for the analysis in (B), because heterogeneity was reduced in subgroup analyses.
doi:10.1371/journal.pone.0037396.g001
ACE Gene Polymorphism and Cough
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e37396were highly heterogeneous (I
2=65.2%, p=0.008) (Table 3).
Therefore, we divided the seven Asian studies into two subgroups
according to the mean age of hypertensives with AECI-related
cough: #60 y (lower median) and .60 y (upper median). The
heterogeneity was reduced in each of the subgroups (I
2=36%,
p=0.212; I
2=0%, p=0.773; respectively), and the FE pooled
ORs were 1.06 (95%CI: 0.82 to 1.37, p=0.668) and 2.39 (95%CI:
1.67 to 3.42, p,0.001) (Figure 1B).
We also compared the II/ID genotypes to the DD genotype
with the extracted data pooled from the 11 studies. The RE and
FE pooled ORs for the dominant model were 1.16 (95%CI: 0.78
to 1.74, p=0.46) and 1.15 (95%CI: 0.91 to 1.46, p=0.25),
respectively, and a moderate heterogeneity was found (I
2=54%,
p=0.02) (Figure 2A, 2B). We did not find heterogeneity when
subgroups were categorized by mean age (Table 3, data not
shown). The follow-up duration of ACEI treatment and the study
population reduced the heterogeneity in one set of subgroups (for
follow-up .2 mo: I
2=0%, for Caucasians: I
2=0%), but the
heterogeneity in the other subgroup was still large (for interval
#2 mo: I
2=67%, for Asians: I
2=65%) (Table 3). For the
dominant model, the FE OR was 0.95 (95%CI: 0.67 to 1.35,
p=0.787) in studies with a .2 mo follow-up duration of ACEI
treatment, and the FE OR was 0.85 (95%CI: 0.58 to 1.25,
p=0.591) in the Caucasian study population. Further, we divided
the 11 studies into three subgroups: Asians with mean age of cases
#60 y, Asians with mean age of cases .60 y, and Caucasians. In
each subgroup, heterogeneity was reduced (I
2=0%, p=0.399;
I
2=0%, p=0.409; I
2=0%, p=0.591; respectively). The FE
pooled ORs were 0.82 (95%CI: 0.55 to 1.24, p=0.348), 2.95
(95%CI: 1.76 to 4.96, p,0.001), and 0.85 (95%CI: 0.58 to 1.25,
p=0.419), respectively (Figure 2B).
There was high heterogeneity when allele I was contrasted with
allele D (I
2=64%, p=0.002), and the RE and FE pooled ORs
were 1.33 (95%CI: 1.04 to1.70, p=0.02) and 1.22 (95%CI: 1.07 to
1.39, p=0.004) (Figure 3A, 3B). No heterogeneity existed within
each of the mean age subgroups. Heterogeneity did exist among
Asian studies and studies with a follow-up duration of #2 mo, but
not among Caucasian studies or studies with a follow-up duration
of .2 mo (Table 3). The FE pooled OR was 0.95 (95%CI: 0.79 to
1.14, p=0.572) in studies with a follow-up duration of .2 mo and
0.99 (95%CI: 0.76 to 1.29, p=0.952) in the Caucasian studies. We
further divided the studies by population and mean ages. Among
the three subgroups (Asians with mean age of cases #60 y, Asians
with mean age of cases .60 y, and Caucasians), no heterogeneity
was detected (I
2=0%, p=0.80; I
2=0%, p=0.82; I
2=5%,
p=0.37; respectively), and the FE pooled ORs were 0.99
(95%CI: 0.81 to 1.20, p=0.90), 2.08 (95%CI: 1.61 to 2.69,
p,0.00001), and 0.99 (95%CI: 0.76 to 1.29, p=0.95), respectively
(Figure 3B).
Publication Bias
A statistical analysis of the Egger test and funnel plots was
performed for all 11 studies (Figure 4). No publication bias was
detected for the contrast of allele I versus D (Egger test, p=0.102).
Discussion
Our meta-analysis of 11 studies revealed that a greater I allele
frequency gave rise to an increased susceptibility to ACEI-related
cough. However, heterogeneity was detected in the 11 studies. The
meta-regression analysis indicated that the effect size was positively
related to the mean age of the subjects and negatively related to
the follow-up duration.
In the subgroup analysis, the association depended on three
variables: (1) Age: a strong association between the ACE I/D
polymorphism and ACEI-related cough was only identified in
studies where the mean age was .60 y, not in studies where the
mean age was #60 y. (2) Follow-up duration: no significant
association existed between the ACE I/D polymorphism and
ACEI-related cough when the follow-up duration was .2 months.
(3) Ethnicity: we did not find any association between the ACE I/
D polymorphism and ACEI-related cough in studies on Caucasian
Table 3. Subgroup analyses for dominant model, recessive model and the allele contrast I versus D.
Intervention
group (n) Dominant model Recessive model The allele contrast I versus D
I
2
RE pooled ORs
(95% CI) PI
2
RE pooled ORs
(95% CI) PI
2
RE pooled OR
(95% CI) P
Mean age
#60 y, low median 5 0% 0.87 (0.64, 1.18) ,0.05 1% 1.12 (0.88, 1.42) ,0.05 0% 1.01 (0.85, 1.20) 0.0001
.60 y, high median 4 0% 2.71 (1.60, 4.61) 0% 2.39 (1.67, 3.43) 0% 2.07 (1.61, 2.68)
Category of ACEIs
enalapril (or major) 4 42% 1.04 (0.52, 2.09) 0.4307 44% 1.52 (0.77, 3.01) 0.6334 70% 1.30 (0.73, 2.35) 0.7469
others 7 63% 1.23 (0.73, 2.09) 58% 1.65 (1.14, 2.40) 67% 1.36 (1.02, 1.81)
Interval of treatment
.2 months 4 0% 0.96 (0.67, 1.37) 0.1155 7% 1.09 (0.81, 1.47) 0.0016 0% 0.95 (0.79, 1.14) 0.0023
#2months 5 67% 1.56 (0.75, 3.24) 0% 2.03 (1.47, 2.80) 50% 1.57 (1.15, 2.13)
Proportion of male
,60%, low median 4 72% 1.59 (0.67, 3.80) 0.2530 0% 1.85 (1.29, 2.66) 0.2895 78% 1.39 (0.90, 2.17) 1.0000
.60%, high median 3 67% 0.87 (0.28, 2.69) 67% 1.46 (0.75, 2.83) 40% 1.39 (0.91, 2.13)
Population
Asian 7 65% 1.49 (0.78, 1.74) 0.0012 65% 1.82 (1.20, 2.74) 0.0298 73% 1.55 (1.11, 2.16) 0.0042
Caucasian 4 0% 0.85 (0.58, 1.25) 0% 1.23 (0.77, 1.98) 5% 0.99 (0.76, 1.31)
doi:10.1371/journal.pone.0037396.t003
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among studies, because the mean age of patients in two of the
Caucasian groups was ,57 y [21,22]; in the other two Caucasian
studies, the age could not be extracted [20,34].
The mechanism for ACEI-related cough was not entirely clear.
We believe that the lower level of tissue ACE (which correlates
with a lower level of blood ACE in the patient) leads to higher
concentrations of ACE substrates (both bradykinin and substance
P), which may contribute to cough development. Bradykinin,
a peptide degraded by ACE, has been suggested to play a major
role in ACEI-related cough [13,14]. The accumulation of
bradykinin may induce activation of proinflammatory peptides
Figure 2. Random effect (A) and fix effect (B) pooled ORs for the dominant model. Subgroup analyses were also carried out (B). In each
subgroup, heterogeneity was reduced.
doi:10.1371/journal.pone.0037396.g002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e37396Figure 3. Random effect (A) and fix effect (B) pooled ORs for the contrast between alleles I and D. Subgroup analyses were also carried
out (B). In each subgroup, heterogeneity was reduced. Allele I was a predictor of ACEI-related cough only in the subgroup of Asians .60 y old.
doi:10.1371/journal.pone.0037396.g003
ACE Gene Polymorphism and Cough
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e37396(e.g., substance P), increase the sensitization of airway sensory
nerves, and increase coughing [6,7,40–42]. Higher levels of
substance P have been found in patients with ACEI-related cough
[43]. The I/D polymorphism of ACE was previously found to be
associated with serum ACE activity. Subjects with genotypes II,
ID, and DD, showed low, intermediate, and high ACE activity,
respectively [15,16]. This supported the notion that the ACE I/D
polymorphism was associated with ACEI-related cough. However,
many other studies did not find an association between the ACE I/
D polymorphism and ACEI-related cough [20–22,37].
Some studies indicated that the ACE I/D polymorphism was
associated with cough sensitivity, rather than ACEI-related cough
(cough sensitivity was defined as a cough reflex response to
stimulation with distilled water) [20,44]. Morice et al. speculated
that ACEI induced a slow, marked reduction in ACE activity, but
the loss of activity might be compensated by other peptide-
degrading pathways. For example, neutral endopeptidase (NEP),
which has been shown to regulate substance P and cough, was one
of the candidates for these compensating pathways [45]. Another
study investigated the association between the ACE gene poly-
morphism and the cough threshold (the number of coughs in
response to capsaicin over a 5-min interval) after cilazapril (an
ACEI) administration; those results supported the notion of
compensation. In that study, serum ACE activities were effectively
inhibited by the ACEI, and ACE activities in the subjects with
genotype II showed significant differences from those with
genotype DD. However, no significant differences in plasma
bradykinin or substance P were found, either before or after the
administration of ACEI in subjects with genotype II or DD [46].
The mean age of the subjects in the study was ,20 y. In youths,
bradykinin can be sufficiently degraded by peptide-degrading
pathways. The degradation of bradykinin by a variety of
peptidases, including dipeptidyl-aminopeptidase IV (DPIV), ami-
nopeptidase N (APN), or neutral aminopeptidase, may be
substantially enhanced in an environment where ACEI has
reduced ACE activity [47].
Based on dominant and recessive gene models, we estimated the
effects of an ACE gene polymorphism on ACEI-related cough. We
found that the I allele of the ACE gene increased the susceptibility
to ACEI-related cough. However, due to heterogeneity among the
11 studies, we performed a meta-regression analysis. This
indicated that the effect size was positively related to the mean
age of the subjects and negatively associated with the follow-up
duration after ACEI treatment. The meta-analysis results also
supported the notion that an ACEI-induced reduction in ACE
activity may lead to bradykinin accumulation, which may
contribute to ACEI-related cough. However, when the ACEI
treatment is long in duration, bradykinin could be degraded by
alternative metabolic pathways, and the ACEI-related cough
might eventually cease or become tolerable. In some long-term
studies, subjects that had recovered from an ACEI-related cough
due to delayed bradykinin degradation may have subsequently
been used as controls. This could have confounded the association
between the ACE I/D polymorphism and ACEI-related cough.
It is not clear why the association between the ACE I/D
polymorphism and ACEI-related cough was more significant in
subjects .60 y compared to those #60 y. It is known that older
subjects have an age-related attenuation of the cough reflex; this
may be related to an attenuation of bradykinin metabolism [48].
Moreover, we speculate that both the formation and the
inactivation of bradykinin may decrease with age. This could
lead to insufficient inactivation of bradykinin with ACEI loading in
older individuals (.60 y). Thus, age-dependent differences in
bradykinin metabolism may contribute to the observed age-related
differences in the association between the ACE I/D polymorphism
and ACEI-related cough.
Our meta-analysis may also provide some guidance in the
clinical use of ACEIs. Young patients with ACEI-related cough
may be advised to adhere to ACEI treatment for 2 or 3 months to
observe whether the cough ceases spontaneously. In cases where
the cough ceases or becomes tolerable, the patient can continue
ACEI therapy. In older patients with ACEI-related cough, it
would also be advisable to adhere to ACEI treatment for a set
period of time. This is because ACE activity directly affects the
cough reflex in older patients, and this effect was negatively
Figure 4. Funnel plot of SE against the log OR for I/D polymorphism.
doi:10.1371/journal.pone.0037396.g004
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individuals with ACE II/ID genotypes [50].
During our manuscript revision, we noted that Dr. Nishio’s
group performed a similar meta-analysis [51]. Interestingly, their
results were consistent with ours in the conclusion that, in
Caucasians, the ACE I/D polymorphism was not associated with
ACEI-related cough. However, the two studies came to different
conclusions for Asians. In their meta-analyses, the ACE I/D
polymorphism was associated with ACEI-related cough in Asians.
In contrast, we concluded the same association, but the effect size
depended on the mean age of the subjects and the follow-up
duration. These results inspired us to understand the mechanism
underlying ACEI-related cough. Note that the eleven studies
included in our meta-analyses were not the same eleven studies
included in Dr. Nishio’s meta-analyses. We identified 18 studies,
but excluded 6 studies, because they were not within Hardy–
Weinberg equilibrium. One other study was excluded because the
frequencies of the genotypic distributions could not be extracted
from the paper (for specifics, see the Results section).
Some limitations of the present study should be mentioned.
First, although we excluded six studies that were not within
Hardy–Weinberg equilibrium, the studies that we included had
inconsistent designs. The categories and dosages of ACEIs varied
among studies, and the follow-up duration ranged from 0.5 to 36
months. Second, the sample sizes were relatively small, and only
five studies were age and sex matched. Thus, the results of the
present meta-analysis should be interpreted with some caution.
Third, some misclassification in case-control studies may have
occurred. Some subjects that could tolerate a slight ACEI-related
cough may have been classified as controls rather than cases.
The present study indicated that the ACE I/D polymorphism
may be a genetic, age-dependent risk factor for ACEI-related
cough. Large case-control studies should be performed to verify
the conclusions of our meta-analysis. Future investigations aimed
at elucidating the age-dependence of the association between the
ACE I/D polymorphism and ACEI-related cough may help to
clarify the mechanism of ACEI-related cough.
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